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Ecto-protein kinases and phosphatases: an
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Abstract
Progress in translational research has led to effective new treatments of a large number of diseases. Despite this
progress, diseases including cancer and cardiovascular disorders still are at the top in death statistics and disorders
such as osteoporosis and osteoarthritis represent an increasing disease burden in the aging population. Novel
strategies in research are needed more than ever to overcome such diseases. The growing field of extracellular
protein phosphorylation provides excellent opportunities to make major discoveries of disease mechanisms that
can lead to novel therapies. Reversible phosphorylation/dephosphorylation of sites in the extracellular domains of
matrix, cell-surface and trans-membrane proteins is emerging as a critical regulatory mechanism in health and
disease. Moreover, a new concept is emerging from studies of extracellular protein phosphorylation: in cells where
ATP is stored within secretory vesicles and released by exocytosis upon cell-stimulation, phosphorylation of extracellular
proteins can operate as a messenger operating uniquely in signaling pathways responsible for long-term cellular
adaptation. Here, we highlight new concepts that arise from this research, and discuss translation of the findings
into clinical applications such as development of diagnostic disease markers and next-generation drugs.
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Introduction
Protein phosphorylation, a reversible posttranslational
modification carried out by the enzymes protein kinases
and phosphatases, is arguably one of the most critical
regulatory biochemical processes operating in physio-
logical systems. The covalent attachment of a phosphate
group by a protein kinase and detachment by a protein
phosphatase is rapid and energy efficient, making pro-
tein phosphorylation one of the most common post-
translational modifications in cells [1]. It is thus not
surprising that intracellular protein kinases have emerged
as one of the most important drug targets, with some 20
drugs on the market and hundreds in clinical trials [2].
It has been estimated that 30% of all human proteins
are phosphorylated at one or another stage during their
lifecycle [3]; however this percentage may be an underesti-
mation since it does not include extracellular proteins. All
preconditions for protein kinases to be active also exist in
the extracellular environment, such as sufficiently high
concentrations of extracellular ATP and a growing body
of evidence is documenting the existence and activity of
these enzymes in extracellular spaces (Figure 1; [4-7]). In
fact, evidence that many prominent kinases and phospha-
tases are located extracellularly has been obtained in-vivo
as well as in-vitro including FAM20C [7], PKA [8,9], PKC
[10,11], CKII [12], alkaline phosphatase [13], tartrate-
resistant acid phosphatase (TRAP) [14] and the PTEN
phosphatase [15] (Table 1). A recent review provides an
in-depth mining of the extensive literature in the field, as
well as of high-throughput mass spectrometry data, de-
scribing known phosphorylated proteins in the extracellu-
lar matrix in many different types of healthy and diseased
tissues and animal species [4]. Major components of the
extracellular matrix and cell surface proteins, including
fibronectin [16], vitronectin [17], osteopontin [18], col-
lagens [19], fibrinogen [20], laminin [21], CD36 [22], β-
amyloid precursor protein (APP) [23], T-cell-receptor
complex (TCR) [24] and many more, have been reported to
be phosphorylated in vitro and in vivo [4]. Evidence that this
enzymatic regulatory activity may be important in extracellular
matrix biology and pathology, cancer growth, tissue engineer-
ing, regenerative medicine, immune response, cardiovascular
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and neuronal biology is growing [4]. These recent find-
ings suggest that phosphorylation of extracellular matrix
proteins provides an important basis for identifying
novel biomarkers and for design of new therapeutic
drugs. In fact, a clinical application based on extracellu-
lar protein-phosphorylation has already been patented
[25], and recent studies propose the involvement of
extracellular protein kinases and phosphatases in diseases
such as cancer, Alzheimer’s, cardiovascular disorders and
others. In this review, we highlight the potential of this
research area as an emerging new field in translational
medicine and for developing novel medical applications.
Small differences can have huge impact
Biomolecules such as insulin or interferon serve as im-
portant drugs today. Seven of the top 10 biopharmaceuti-
cals in 2012 were indeed biomolecular drugs, according to
FiercePharma statistics. These include extracellular pro-
teins. For example, recombinant BMP-2, an FDA ap-
proved drug, is routinely used to induce bone formation
in bone defects [27]. Recombinant BMP-7 is also FDA ap-
proved as an alternative to autografts [28]. The design and
production of such drugs need to be precise. Even small
differences in structure can have a huge impact on their
performance. The phosphorylation state of these proteins
is one of these critical factors. These drugs are produced
as recombinant proteins; therefore their phosphorylation
state may vary from batch to batch. Our analyses show
that both BMP-2 and BMP-7 can occur in phosphorylated
states in human biosamples; however when they are used
in the clinic, this modification is largely ignored. Paying at-
tention to their state of phosphorylation may have signifi-
cant consequences for their effective activities. Similar
effects should be considered when growing cells in culture
on surfaces coated with extracellular proteins; a standard
method used today in basic research as well as in transla-
tional science. The phosphorylation state of matrix pro-
teins can vary from batch to batch of purified or
commercially available protein substrates for cell cul-
ture. Such variations seem minor, but they can cause
significant differences in cell behavior. For example,
while the phosphorylated form of the extracellular
protein vitronectin promotes cell adhesion, the non-
phosphorylated form inhibits cell adhesion [29]. Simi-
larly, the phosphorylation state of extracellular proteins
was reported to regulate the binding affinity as well as
specificity in protein activity. For example, phosphoryl-
ation of CD36 by PKC at the position T92 leads to
Table 1 Reported prominent extracellular protein kinases
and phosphatases
Kinase Sample Reference
PKA serum from cancer patient [8,9]
PKC human platelets, hippocampal
neurons
[10,26]
CKII human prostatic cancer cell line [12]
FAM20C HEK293T [7]
Alkaline
phosphatase
human serum [13]
PTEN primary human breast tumor [15]
TRAP human serum [14]
Figure 1 Potential scenarios of extracellular protein phosphorylation. Potential scenarios of extracellular protein phosphorylation are shown.
Extracellular ATP can enter the extracellular matrix (ECM) through vesicle secretion or cell lysis [4]. Extracellular proteins or the extracellular domains of
cell surface and trans-membrane proteins may be phosphorylated during biosynthesis and then exported, or phosphorylated after release or
appearance at the cell surface by exo- and ecto-kinases, respectively.
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stronger binding to collagen, but results in loss of throm-
bospondin binding. The effect is reversible and suggests a
regulated mechanism [22]. Finally, MMP2 enzyme activity
was shown to be regulated by extracellular PKC phos-
phorylation, in that dephosphorylation leads to increased
activity, and phosphorylation inhibits the activity [30,31].
In all translational studies and clinical developments
where extracellular proteins are involved, their phos-
phorylation state might have substantial effects on the
outcomes and needs to be taken into account.
Impact on diseases
The activity of extracellular protein kinases has been de-
scribed in the context of several physiological processes.
These include leukocyte and macrophage adhesion and
migration [32,33], fertilization [34], platelet function
[35,36], blood coagulation [37], complement system
function [38], receptor specificity and sensitivity [29],
neuronal development and adaptation [39], synaptic
plasticity and memory formation [40], (for a review see
[4]). The involvement of extracellular protein kinases
has also been reported for a number of diseases (Table 2).
For example, in Alzheimer’s phosphorylation of amyloid-
β-peptides by ecto-PKA at the cell surface and in the cere-
brospinal fluid promotes the formation of toxic aggregates
leading to increased aggregation and decreased clearance
[41]. Phosphorylated amyloid-β-peptides have been de-
tected in the brains of Alzheimer’s disease patients and
this may offer new ways to target the disease. In prostate
or breast cancer patients, enhanced kinase levels and ac-
tivities are found in sera. It has been shown that tumor
cells secrete cAMP-dependent PKA; however, the function
of the secreted form is unknown [8,9,42]. Analysis of
serum from a large number of Schizophrenia patients re-
vealed 72 phosphoproteins and phosphorylation-specific
changes in 59 of these proteins compared with samples
from matched healthy controls [43].
Extracellular protein phosphorylation is believed to
play a role in cardiovascular disease [46,52]. For ex-
ample, protein kinase C and protein kinase A have been
detected on the surface of platelets. Furthermore, plate-
lets have been shown to selectively secrete PKC iso-
zymes as well as PKA. While their mechanisms of action
have not yet been fully determined, current data suggest
an important role in fibrinolysis [35,37,46,52]. A particu-
larly well-studied example of the important function of
an extracellular kinase is the Raine syndrome, caused by
loss-of-function mutations in the extracellular kinase
FAM20C. This leads to biomineralization defects [7].
Another well-studied example is a mutation in enamelin
resulting in loss of a phosphorylation site for FAM20C.
The phosphorylation at this site is necessary for binding
of calcium and the loss of this calcium binding site in
enamelin causes Amelogenesis Imperfecta [47]. Since
the role of extracellular protein phosphorylation was
barely considered in disease etiology in the past, extra-
cellular protein phosphorylation may play a role in many
more diseases than currently known.
Novel disease markers and drug targets
The activities of extracellular protein phosphatases are
routinely measured by an alkaline phosphatase blood
test in the clinic, as a disease marker for liver diseases,
bone disorders or cancer. In addition, the use of tartrate-
resistant acid phosphatase (TRAP), produced by osteo-
clasts, is being discussed as a marker [13,14]. Similarly, an
assay for extracellular protein kinases have been proposed
(and recently patented) as biomarker for specific cancer
types [25]. Remarkably, the activity of extracellular protein
kinases in sera of melanoma patients correlates with the
appearance and size of the tumor and is significantly de-
creased after removal of the tumor [9]. Not only cancer
but also other diseases might be detected earlier by utiliz-
ing the phosphorylation state of extracellular proteins as
markers. A clear difference in the phosphorylation pattern
Table 2 Extracellular phosphorylation in different diseases
Disease Kinase Protein Effect Reference
Alzheimer’s disease ecto-PKA amyloid-β-peptides enhanced aggregation of amyloid-β-peptides [41]
Prostate cancer cAMP-dependent PKA [44]
Breast cancer cAMP-dependent PKC [11]
Schizophrenia 72 proteins [45]
Thrombosis and atherosclerosis F11R aka JAM-A [46]
Raine syndrome FAM20C SIBLINGs [7]
Amelogenesis imperfecta FAM20C enamelin calcium binding affected [47]
Bacterial infection PKC [48]
Parasite infection PKC, CK2 [49,50]
HIV ectophosphatase [51]
Memory formation ecto-PKC [26]
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of serum proteins in sera of schizophrenia patients was
mentioned above [45]. Further studies detected 502 serum
proteins to be phosphorylated in sera of 80 healthy indi-
viduals and discussed the phosphorylation pattern as po-
tential disease marker [53-55]. A large number of studies
describing the activity of extracellular kinases in parasites
and bacteria open the door to the discovery of novel
methods for detecting and treating infections [48,49]. Fur-
ther progress in this area could lead to novel and/or more
reliable biomarker assays in clinical studies of cancer and
other diseases and new therapies [25].
The location of extracellular protein kinases provides a
unique advantage for drug development. Potential inhib-
itors or activators of extracellular kinases and phospha-
tases can be designed purposefully as lipid insoluble
molecules that are unable to penetrate into cells through
the plasma membrane. This may provide greater selectivity
and fewer side effects, as it will prevent interaction of these
drugs with intracellular kinases [56]. An excellent example
of this kind of new drug would be a water-soluble,
membrane-impermeable peptide or peptido-mimetic based
on the sequence and tertiary structure of the region sur-
rounding a critical phosphorylated amino-acid residue lo-
cated in the extracellular domain of a specific protein
substrate of an ecto- or exo-protein kinase [56].
Analyses of drug-target interactions are crucial during
the drug design phase. Protein phosphorylation is known
to regulate protein-protein interaction in many cases in-
side the cell [57]. During the design of potential drugs
for targeting extracellular or cell surface proteins, the
phosphorylation state of the proteins also needs to be
taken into account. An example of how important the
phosphorylation state of a drug may be is demonstrated
by the Multiple Sclerosis drug Fingolimod (FTY720); its
phosphorylation state is believed to be regulated by the
ecto-phosphatase LPP3 in vivo [58].
A novel concept revealed by extracellular protein
phosphorylation
In several cell types ATP is stored within secretory vesicles
and released by exocytosis upon cell-stimulation. Repeti-
tive, high frequency stimulation of these cells produces
unusually high concentrations of ATP in the extracellular
space, and particularly in synaptic-clefts between neurons.
Such events do not occur usually during the course of
routine cellular communications. Instead, they represent
unique biochemical signals responsible for triggering
adaptive processes with long-lasting consequences [59]. In
the next step, extracellular protein kinase activity that is
dependent on these higher ATP concentrations produces
a phosphorylation-dependent event required for the in-
duction of long-term adaptive changes [39,56,59,60].
Platelet and neuronal activities have been most studied in
regard to this aspect of extracellular phosphorylation.
Massive stimulation of localized platelets produces high
concentrations of extracellular ATP during blood coagula-
tion and atherosclerotic plaque formation, and extracellu-
lar protein kinase activities have been implicated in both
[56]. High frequency stimulation of neurons in the hippo-
campus induces a memory-related adaptive process called
long term potentiation (LTP), involving high ATP concen-
trations in the synaptic-cleft [60]. LTP is a physiological
measure of memory formation in the brain that requires
an extracellular protein kinase C activity [26]. Similarly,
the same concept suggests that high levels of extracellular
ATP produced by neurons during seizures may trigger
extracellular phosphorylation activity involved in the eti-
ology of Epileply.
Conclusions and future outlook
Recent advances in the research of reversible extracellular
protein phosphorylation activity provide unique opportun-
ities for translational medicine to design novel drugs and
identify new disease markers. While the mechanisms of
action of extracellular protein kinases and phosphatases
are being uncovered and complete knowledge of their
physiological roles requires further investigation, clinical
studies already show their potential as novel biomarkers
and drug targets in diseases such as cancer [44], neuronal
[5,39,41,56] and cardiovascular disorders [10,33,46,52].
Initial studies and patents show encouraging results re-
garding the performance of such biomarkers compared to
conventional markers [25]. The fact that secreted alkaline
phosphatase is routinely used as a biomarker in clinics
today suggests that other secreted protein kinases and
phosphatases will be used as novel markers in the future
[61]. A large number of extracellular proteins have been
reported in phosphorylated states as a result of interac-
tions with yet unknown extracellular protein kinases. It is
thus expected that many more active kinases will be dis-
covered in the extracellular environment. Finally, more
directed studies may uncover the involvement of extracel-
lular phosphorylation in many more diseases than those
that are currently known and open up new avenues for
novel therapies.
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